"EGFR CREAM" . . . . . . "RIV/26003279:_____/11:#0000009!RIV11-MPO-26003279" . "1"^^ . . "Prevention, PRIDE syndrom, EGFR inhibitors"@en . "219178" . "2"^^ . "Prepar\u00E1t EGFR CREAM je prioritn\u011B vyvinut pro zvl\u00E1d\u00E1n\u00ED ko\u017En\u00ED toxicity p\u0159i l\u00E9\u010Db\u011B tzv. EGFR inhibitory. EGFR inhibitory se pou\u017E\u00EDvaj\u00ED v l\u00E9\u010Db\u011B malign\u00EDch onemocn\u011Bn\u00ED a jejich nej\u010Dast\u011Bj\u0161\u00EDm ne\u017E\u00E1douc\u00EDm \u00FA\u010Dinkem je ko\u017En\u00ED exant\u00E9m."@cs . "F\u00E1ze testov\u00E1n\u00ED" . "Proven technology \u2013 company standard PN OT \u201310-2010 due to utility design no. 22119"@en . "Proven technology \u2013 company standard PN OT \u201310-2010 due to utility design no. 22119"@en . "Ov\u011B\u0159en\u00E1 technologie - podnikov\u00E1 norma PN OT \u2013 10-2010 dle u\u017Eitn\u00E9ho vzoru \u010D. z\u00E1pisu 22119" . . "[D3FC9DED7E8D]" . . "Ov\u011B\u0159en\u00E1 technologie - podnikov\u00E1 norma PN OT \u2013 10-2010 dle u\u017Eitn\u00E9ho vzoru \u010D. z\u00E1pisu 22119"@cs . . "Prepar\u00E1t EGFR CREAM je prioritn\u011B vyvinut pro zvl\u00E1d\u00E1n\u00ED ko\u017En\u00ED toxicity p\u0159i l\u00E9\u010Db\u011B tzv. EGFR inhibitory. EGFR inhibitory se pou\u017E\u00EDvaj\u00ED v l\u00E9\u010Db\u011B malign\u00EDch onemocn\u011Bn\u00ED a jejich nej\u010Dast\u011Bj\u0161\u00EDm ne\u017E\u00E1douc\u00EDm \u00FA\u010Dinkem je ko\u017En\u00ED exant\u00E9m." . . "\u0160andrikov\u00E1, Viera" . "ve vlastnictv\u00ED spole\u010Dnosti C2P" . "Ov\u011B\u0159en\u00E1 technologie - podnikov\u00E1 norma PN OT \u2013 10-2010 dle u\u017Eitn\u00E9ho vzoru \u010D. z\u00E1pisu 22119" . . "Ov\u011B\u0159en\u00FD v\u00FDrobn\u00ED postup (PN OT \u2013 10-2010 ) Protokol o zk. ko\u017En\u00ED citlivosti \u010D. 291110 Protokol o mikrob. zk. \u010D. 3432/10 \u010D\u00EDslo vzorku 7743 (zk.lab.\u010D. 082 akreditovan\u00E1 \u010CIA). - Sml. o vyu\u017Eit\u00ED v\u00FDsledk\u016F v\u00FDzkumu a v\u00FDvoje 2010/FI-IM5/195" . . "Ov\u011B\u0159en\u00E1 technologie - podnikov\u00E1 norma PN OT \u2013 10-2010 dle u\u017Eitn\u00E9ho vzoru \u010D. z\u00E1pisu 22119"@cs . . . . . . . "EGFR CREAM is developed with priority to manage skin toxicity cause by EGFR inhibitors. EGFR inhibitors are commonly use in treatment of malignant diseases. The most common toxicity is skin exanthema."@en . "Hrom\u00E1dka, R\u00F3bert" . "RIV/26003279:_____/11:#0000009" . . "P(FI-IM5/195)" . .